OncoSec Medical Incorporated (ONCS) Stock Price, Quote, News and Overview
NASDAQ:ONCS - Nasdaq - US68234L4059 - Common Stock - Currency: USD
ONCS Quote, Performance and Key Statistics
0.2772
+0.07 (+31.87%)
The current stock price of ONCS is 0.2772 USD. In the past month the price decreased by -44.42%. In the past year, price decreased by -98.4%.
ONCS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.83 | 342.01B | ||
| AMGN | AMGEN INC | 14.32 | 152.57B | ||
| GILD | GILEAD SCIENCES INC | 13.34 | 128.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1720.21 | 128.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.32 | 64.50B | ||
| ARGX | ARGENX SE - ADR | 336.79 | 39.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.19B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.62B | ||
| NTRA | NATERA INC | N/A | 20.46B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.19B | ||
| BIIB | BIOGEN INC | 7.34 | 17.70B |
Related stock screener links
About ONCS
Company Profile
OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. The company is headquartered in Ewing, New Jersey and currently employs 40 full-time employees. The company went IPO on 2015-05-29. The firm is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral EP delivery devices, such as the OncoSec Medical System (OMS) EP device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO) with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.
Company Info
OncoSec Medical Incorporated
820 Bear Tavern Road
Ewing NEW JERSEY 08534 US
CEO: Margaret Dalesandro
Employees: 40
Company Website: https://oncosec.com/
Phone: 18582107333.0
OncoSec Medical Incorporated / ONCS FAQ
What is the stock price of OncoSec Medical Incorporated today?
The current stock price of ONCS is 0.2772 USD. The price increased by 31.87% in the last trading session.
What is the ticker symbol for OncoSec Medical Incorporated stock?
The exchange symbol of OncoSec Medical Incorporated is ONCS and it is listed on the Nasdaq exchange.
On which exchange is ONCS stock listed?
ONCS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OncoSec Medical Incorporated stock?
6 analysts have analysed ONCS and the average price target is 5.1 USD. This implies a price increase of 1739.83% is expected in the next year compared to the current price of 0.2772. Check the OncoSec Medical Incorporated stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OncoSec Medical Incorporated worth?
OncoSec Medical Incorporated (ONCS) has a market capitalization of 1.65M USD. This makes ONCS a Nano Cap stock.
How many employees does OncoSec Medical Incorporated have?
OncoSec Medical Incorporated (ONCS) currently has 40 employees.
Should I buy OncoSec Medical Incorporated (ONCS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONCS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONCS, evaluating the profitability, health, valuation and growth aspects
- OncoSec Medical Incorporated (ONCS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OncoSec Medical Incorporated (ONCS) Sales and EPS estimates to see what analysts future expectations are.
- OncoSec Medical Incorporated (ONCS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OncoSec Medical Incorporated (ONCS) Insider and Institutional Ownership to learn about the owners and their transactions.
- OncoSec Medical Incorporated (ONCS) Stock Chart to make your own analysis
- OncoSec Medical Incorporated (ONCS) Latest news and press-releases to stay up to date.
Does OncoSec Medical Incorporated (ONCS) stock pay dividends?
ONCS does not pay a dividend.
What is the Price/Earnings (PE) ratio of OncoSec Medical Incorporated (ONCS)?
OncoSec Medical Incorporated (ONCS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.14).
ONCS Technical Analysis
ONCS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ONCS. Both the profitability and financial health of ONCS have multiple concerns.
ONCS Financial Highlights
Over the last trailing twelve months ONCS reported a non-GAAP Earnings per Share(EPS) of -19.14. The EPS increased by 39.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ONCS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ONCS. The Buy consensus is the average rating of analysts ratings from 6 analysts.